Multiomics Market Size, Trends and Insights By Type (Single-cell Multiomics, Bulk Multiomics), By Platform (Genomics, Transcriptomics, Proteomics, Metabolomics, Integrated Omics Platforms), By Application (Cell Biology, Oncology, Neurology, Immunology), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Reports Description
Global Multiomics Market was valued at USD 2.7 Billion in 2024 and is expected to reach USD 7.6 Billion by 2033, at a CAGR of 15.2% during the forecast period 2024 – 2033.
Multiomics is the study of biological systems using various omics technologies such as genomics, transcriptomics, proteomics, metabolomics, and epigenomics, among others. Each omic field focuses on a unique element of biological molecules.
Multiomics Market: Growth Factors
High demand in pharmaceuticals
The strong demand for multiomic solutions in pharmaceuticals is driving significant growth in the multiomic market. Multiomics is the complete analysis of several omics data sets, including genomes, transcriptomics, proteomics, metabolomics, and epigenomics, to gain a holistic knowledge of biological systems.
In the pharmaceutical sector, this method provides unrivalled insights into illness processes, treatment reactions, and patient variation. Integrating data from numerous omics levels allows researchers to unravel intricate molecular relationships, identify biomarkers for illness diagnosis and prognosis, and discover novel therapeutic targets.
The increased frequency of complicated diseases such as cancer, cardiovascular ailments, and neurological conditions, where standard single-omics approaches may not provide significant insights, is driving demand for multiomic solutions even more.
Furthermore, advances in high-throughput omics technologies, data analytics, and computational modelling are improving the feasibility and scalability of multiomic investigations, which is driving the growth of the multiomic market in the pharmaceutical industry.
Growing adoption in crop breeding
The growing use of multiomics approaches in crop breeding is profoundly transforming agricultural innovation and production. Researchers get a complete understanding of plant life at the molecular level by combining multiple omics disciplines such as genomics, transcriptomics, proteomics, metabolomics, and epigenomics.
This comprehensive method allows for an exact definition of plant features, identification of key genes responsible for desirable traits, and deciphering complex regulatory networks that govern crop development, stress responses, and yield potential.
Furthermore, multiomics techniques speed the breeding process by allowing for high-throughput screening of genetic variants and phenotype-genotype correlations, reducing the time required to generate new cultivars.
The use of multiomics in crop breeding not only speeds up the production of resilient and high-yielding crops, but also addresses global issues including food security, climate change, and sustainable agriculture.
As a result, the increasing adoption of multiomics techniques in crop breeding is propelling the multiomics market forward, as stakeholders across the agricultural sector recognize its potential to revolutionize the enhancement of crops and meet the growing demand for nutritious and sustainable food production.
Multiomics Market: Restraints
High setup cost
High startup expenses associated with multiomics research can severely impede market expansion. Multiomics, which combines several omics technologies including genomes, transcriptomics, proteomics, metabolomics, and epigenomics, provides a holistic understanding of biological systems.
However, the deployment of multiomics techniques necessitates a significant investment in advanced equipment, specialized software, and highly trained individuals. Furthermore, the intricacy of integrating data from different omics layers necessitates strong computational infrastructure and knowledge, which raises the financial burden.
As a result, many researchers may lack the means to create and maintain multiomics facilities, limiting access to advanced techniques and hampering wider adoption and innovation in the area.
Solving these cost barriers through collaborative efforts, innovations in technology that reduce expenses, and funding initiatives could lead to increased participation and advancement in multiomics research, ultimately driving its wider use and impact in understanding complex biological systems.
Multiomics Market: Opportunities
Demand for personalized medicines
The growing demand for personalized treatments is a major factor driving the multiomics market forward. Personalized medicine seeks to match medical treatments to individual factors such as genetic makeup, lifestyle, and environment to increase efficacy while minimizing side effects.
Multiomics is an interdisciplinary technique that integrates data from numerous omics disciplines, including genomes, transcriptomics, proteomics, metabolomics, and epigenomics, to provide full insights into an individual’s biological profile.
Using multiomics technologies, healthcare practitioners can acquire a more individualized understanding of the complex biological mechanisms driving diseases and therapeutic responses. This permits the discovery of biomarkers for disease diagnosis, prognosis, and treatment selection, resulting in more precise and successful therapeutic interventions.
Moreover, the introduction of high-throughput sequencing and sophisticated analytical techniques has dramatically lowered the cost and time necessary for multiomics analysis, making it more practical for everyday clinical applications.
As an outcome, the incorporation of multiomics techniques into healthcare practices is becoming more common, fuelling the growth of the multiomics market as it plays a critical part in customized medicine.
Multiomics Market: Segmentation Analysis
The global Multiomics market is segmented by type, platform, application, and region. Based on type, the market is classified into single-cell multi-omics and bulk multi-omics. Bulk Multi-Omics dominated the market in 2023 with a market share of 60.3% and is expected to keep its dominance during the forecast period 2024-2033.
Bulk multi-omics, which integrates several omics datasets (e.g., genomes, transcriptomics, proteomics, metabolomics, and epigenomics) at scale, is transforming biomedical research and personalized treatment.
Bulk multi-omics provides a holistic picture of biological systems, allowing researchers to identify intricate relationships and patterns at several molecular levels, leading to greater insights into disease causes, treatment responses, and biomarker development.
The rise of bulk multi-omics applications, fuelled by advances in high-throughput sequencing, mass spectrometry, and bioinformatics tools, is propelling the multiomics market forward.
As scientists increasingly recognize the value of multi-omics approaches in addressing complex biological questions, demand for bulk multi-omics solutions is expected to drive market growth, with implications ranging from basic research to medical diagnostics and precision medicine initiatives.
Based on platform, the market is classified into genomics, transcriptomics, proteomics, metabolomics and integrated omics platforms. Genomics dominated the market in 2023 with a market share of 30.5% and is expected to keep its dominance during the forecast period 2024-2033.
Genomics, the study of an organism’s entire DNA sequence, is critical to driving the multiomics business, which combines data from several omics domains such as genomics, transcriptomics, proteomics, metabolomics, and epigenomics.
Genomics generates foundational data by sequencing an organism’s genome, exposing its genetic blueprint and variations. By merging genomic data with other omics information, researchers get a comprehensive understanding of biological systems, disease processes, and tailored medicine.
For example, integrating genomics and transcriptomics allows for the investigation of transcription patterns, whereas combining genomics and proteomics allows for the identification of proteins encoded by genes. These multiomics approaches enable a better understanding of complex biological processes, which speeds up drug discovery, biomarker identification, and precision medicine initiatives.
Based on application, the market is classified into oncology, cell biology, neurology, immunology and others. Oncology dominated the market in 2023 with a market share of 34.5% and is expected to keep its dominance during the forecast period 2024-2033.
Oncology is moving the multiomics market ahead due to the requirement for comprehensive, individualized cancer treatments. Multiomics, which combines data from several “-omics” disciplines like genomes, transcriptomics, proteomics, and metabolomics, provides a comprehensive perspective of cancer biology, allowing for a better understanding of the illness and its processes.
Combining genomic, transcriptomic, and proteomic data allows clinicians to find complicated molecular pathways driving cancer growth, resistance mechanisms, and possible treatment targets. This multiomic approach not only improves the knowledge of cancer biology but also allows for the discovery and development of new therapies and precision medicine tactics, ultimately improving patient outcomes and changing cancer care.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 2.7 Billion |
| Projected Market Size in 2033 | USD 7.6 Billion |
| Market Size in 2023 | USD 2.3 Billion |
| CAGR Growth Rate | 15.2% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Type, Platform, Application and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Multiomics Market: Regional Analysis
By region, Multiomics market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East & Africa. North America dominated the global Multiomics market in 2023 with a market share of 39.1% and is expected to keep its dominance during the forecast period 2024-2033.
North America dominates the multiomics industry due to a combination of strong research infrastructure, technological developments, and significant expenditure in healthcare. The region has a large network of premier academic institutions, research centres, and pharmaceutical businesses, which promotes innovation and collaboration in multiomics research.
Furthermore, North America’s emphasis on precision medicine and individualized healthcare has accelerated the use of multiomics techniques, which allow for complete investigation of biological systems at numerous molecular levels.
The United States, in particular, stands out as a major contributor to the growth of the multiomics market, because of its strong biotechnology sector and a favourable regulatory environment that encourages the development and commercialization of multiomics technologies and services.
Moreover, the region’s high healthcare spending and growing emphasis on genetic medicine increase demand for multiomics solutions that provide insights into disease causes, biomarker development, and therapeutic targeting.
Overall, North America’s leadership in multiomics research and commitment to improving healthcare through molecular analysis position it as a key driver of the global multiomics market.
Multiomics Market: Recent Developments
- In January 2024, BD announced its partnership with Hamilton Company. The company’s collaboration focuses on developing robotics-compatible and automated application reagent kits to standardize and eliminate human error in large-scale single-cell multiomics studies.
- In January 2024, Thermo Fisher Scientific Inc. collaborated with Akoya Biosciences, Inc. The agreement simplifies the procedure of whole-slide, multiomic imaging. This combination technique provides a more thorough understanding of cell phenotypes and circumstances by studying protein and RNA, which is critical in the field of cancer research.
- In November 2023, Illumina launched an improved liquid biopsy technique meant to enable thorough genetic profiling of solid cancers.
List of the prominent players in the Multiomics Market:
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Agilent Technologies Inc.
- Qiagen N.V.
- PerkinElmer Inc.
- Bio-Rad Laboratories Inc.
- Bruker Corporation
- Waters Corporation
- Danaher Corporation
- Roche Holding AG
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences of California Inc.
- Eurofins Scientific
- BGI Group
- GenScript Biotech Corporation
- NanoString Technologies Inc.
- Takara Bio Inc.
- GE Healthcare
- Beckman Coulter Inc.
- 10x Genomics Inc.
- Others
These key players are adopting various growth strategies such as mergers & acquisitions, joint ventures, expansion, strategic alliances, new product launches, etc. to enhance their business operations and revenues.
The Multiomics Market is segmented as follows:
By Product & Service
- Products
- Instruments
- Consumables
- Software
- Services
By Type
- Single-cell Multiomics
- Bulk Multiomics
By Platform
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Integrated Omics Platforms
By Application
- Cell Biology
- Oncology
- Neurology
- Immunology
By End-use
- Academic and Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global Multiomics Market, (2024 – 2033) (USD Billion)
- 2.2 Global Multiomics Market: snapshot
- Chapter 3. Global Multiomics Market – Industry Analysis
- 3.1 Multiomics Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 High demand in pharmaceuticals
- 3.2.2 Growing adoption in crop breeding
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Platform
- 3.7.3 Market Attractiveness Analysis By Application
- Chapter 4. Global Multiomics Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Multiomics Market: Company Market Share, 2023
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, collaboration, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Multiomics Market – Type Analysis
- 5.1 Global Multiomics Market Overview: By Type
- 5.1.1 Global Multiomics Market Share, By Type, 2023 and 2033
- 5.2 Single-cell Multiomics
- 5.2.1 Global Multiomics Market by Single-cell Multiomics, 2024 – 2033 (USD Billion)
- 5.3 Bulk Multiomics
- 5.3.1 Global Multiomics Market by Bulk Multiomics, 2024 – 2033 (USD Billion)
- 5.1 Global Multiomics Market Overview: By Type
- Chapter 6. Global Multiomics Market – Platform Analysis
- 6.1 Global Multiomics Market Overview: By Platform
- 6.1.1 Global Multiomics Market Share, By Platform, 2023 and 2033
- 6.2 Genomics
- 6.2.1 Global Multiomics Market by Genomics, 2024 – 2033 (USD Billion)
- 6.3 Transcriptomics
- 6.3.1 Global Multiomics Market by Transcriptomics, 2024 – 2033 (USD Billion)
- 6.4 Proteomics
- 6.4.1 Global Multiomics Market by Proteomics, 2024 – 2033 (USD Billion)
- 6.5 Metabolomics
- 6.5.1 Global Multiomics Market by Metabolomics, 2024 – 2033 (USD Billion)
- 6.6 Integrated Omics Platforms
- 6.6.1 Global Multiomics Market by Integrated Omics Platforms, 2024 – 2033 (USD Billion)
- 6.1 Global Multiomics Market Overview: By Platform
- Chapter 7. Global Multiomics Market – Application Analysis
- 7.1 Global Multiomics Market Overview: By Application
- 7.1.1 Global Multiomics Market Share, By Application, 2023 and 2033
- 7.2 Cell Biology
- 7.2.1 Global Multiomics Market by Cell Biology, 2024 – 2033 (USD Billion)
- 7.3 Oncology
- 7.3.1 Global Multiomics Market by Oncology, 2024 – 2033 (USD Billion)
- 7.4 Neurology
- 7.4.1 Global Multiomics Market by Neurology, 2024 – 2033 (USD Billion)
- 7.5 Immunology
- 7.5.1 Global Multiomics Market by Immunology, 2024 – 2033 (USD Billion)
- 7.1 Global Multiomics Market Overview: By Application
- Chapter 8. Multiomics Market – Regional Analysis
- 8.1 Global Multiomics Market Regional Overview
- 8.2 Global Multiomics Market Share, by Region, 2023 & 2033 (USD Billion)
- 8.3. North America
- 8.3.1 North America Multiomics Market, 2024 – 2033 (USD Billion)
- 8.3.1.1 North America Multiomics Market, by Country, 2024 – 2033 (USD Billion)
- 8.3.1 North America Multiomics Market, 2024 – 2033 (USD Billion)
- 8.4 North America Multiomics Market, by Type, 2024 – 2033
- 8.4.1 North America Multiomics Market, by Type, 2024 – 2033 (USD Billion)
- 8.5 North America Multiomics Market, by Platform, 2024 – 2033
- 8.5.1 North America Multiomics Market, by Platform, 2024 – 2033 (USD Billion)
- 8.6 North America Multiomics Market, by Application, 2024 – 2033
- 8.6.1 North America Multiomics Market, by Application, 2024 – 2033 (USD Billion)
- 8.7. Europe
- 8.7.1 Europe Multiomics Market, 2024 – 2033 (USD Billion)
- 8.7.1.1 Europe Multiomics Market, by Country, 2024 – 2033 (USD Billion)
- 8.7.1 Europe Multiomics Market, 2024 – 2033 (USD Billion)
- 8.8 Europe Multiomics Market, by Type, 2024 – 2033
- 8.8.1 Europe Multiomics Market, by Type, 2024 – 2033 (USD Billion)
- 8.9 Europe Multiomics Market, by Platform, 2024 – 2033
- 8.9.1 Europe Multiomics Market, by Platform, 2024 – 2033 (USD Billion)
- 8.10 Europe Multiomics Market, by Application, 2024 – 2033
- 8.10.1 Europe Multiomics Market, by Application, 2024 – 2033 (USD Billion)
- 8.11. Asia Pacific
- 8.11.1 Asia Pacific Multiomics Market, 2024 – 2033 (USD Billion)
- 8.11.1.1 Asia Pacific Multiomics Market, by Country, 2024 – 2033 (USD Billion)
- 8.11.1 Asia Pacific Multiomics Market, 2024 – 2033 (USD Billion)
- 8.12 Asia Pacific Multiomics Market, by Type, 2024 – 2033
- 8.12.1 Asia Pacific Multiomics Market, by Type, 2024 – 2033 (USD Billion)
- 8.13 Asia Pacific Multiomics Market, by Platform, 2024 – 2033
- 8.13.1 Asia Pacific Multiomics Market, by Platform, 2024 – 2033 (USD Billion)
- 8.14 Asia Pacific Multiomics Market, by Application, 2024 – 2033
- 8.14.1 Asia Pacific Multiomics Market, by Application, 2024 – 2033 (USD Billion)
- 8.15. Latin America
- 8.15.1 Latin America Multiomics Market, 2024 – 2033 (USD Billion)
- 8.15.1.1 Latin America Multiomics Market, by Country, 2024 – 2033 (USD Billion)
- 8.15.1 Latin America Multiomics Market, 2024 – 2033 (USD Billion)
- 8.16 Latin America Multiomics Market, by Type, 2024 – 2033
- 8.16.1 Latin America Multiomics Market, by Type, 2024 – 2033 (USD Billion)
- 8.17 Latin America Multiomics Market, by Platform, 2024 – 2033
- 8.17.1 Latin America Multiomics Market, by Platform, 2024 – 2033 (USD Billion)
- 8.18 Latin America Multiomics Market, by Application, 2024 – 2033
- 8.18.1 Latin America Multiomics Market, by Application, 2024 – 2033 (USD Billion)
- 8.19. The Middle-East and Africa
- 8.19.1 The Middle-East and Africa Multiomics Market, 2024 – 2033 (USD Billion)
- 8.19.1.1 The Middle-East and Africa Multiomics Market, by Country, 2024 – 2033 (USD Billion)
- 8.19.1 The Middle-East and Africa Multiomics Market, 2024 – 2033 (USD Billion)
- 8.20 The Middle-East and Africa Multiomics Market, by Type, 2024 – 2033
- 8.20.1 The Middle-East and Africa Multiomics Market, by Type, 2024 – 2033 (USD Billion)
- 8.21 The Middle-East and Africa Multiomics Market, by Platform, 2024 – 2033
- 8.21.1 The Middle-East and Africa Multiomics Market, by Platform, 2024 – 2033 (USD Billion)
- 8.22 The Middle-East and Africa Multiomics Market, by Application, 2024 – 2033
- 8.22.1 The Middle-East and Africa Multiomics Market, by Application, 2024 – 2033 (USD Billion)
- Chapter 9. Company Profiles
- 9.1 Thermo Fisher Scientific Inc.
- 9.1.1 Overview
- 9.1.2 Financials
- 9.1.3 Product Portfolio
- 9.1.4 Business Strategy
- 9.1.5 Recent Developments
- 9.2 Illumina Inc.
- 9.2.1 Overview
- 9.2.2 Financials
- 9.2.3 Product Portfolio
- 9.2.4 Business Strategy
- 9.2.5 Recent Developments
- 9.3 Agilent Technologies Inc.
- 9.3.1 Overview
- 9.3.2 Financials
- 9.3.3 Product Portfolio
- 9.3.4 Business Strategy
- 9.3.5 Recent Developments
- 9.4 Qiagen N.V.
- 9.4.1 Overview
- 9.4.2 Financials
- 9.4.3 Product Portfolio
- 9.4.4 Business Strategy
- 9.4.5 Recent Developments
- 9.5 PerkinElmer Inc.
- 9.5.1 Overview
- 9.5.2 Financials
- 9.5.3 Product Portfolio
- 9.5.4 Business Strategy
- 9.5.5 Recent Developments
- 9.6 Bio-Rad Laboratories Inc.
- 9.6.1 Overview
- 9.6.2 Financials
- 9.6.3 Product Portfolio
- 9.6.4 Business Strategy
- 9.6.5 Recent Developments
- 9.7 Bruker Corporation
- 9.7.1 Overview
- 9.7.2 Financials
- 9.7.3 Product Portfolio
- 9.7.4 Business Strategy
- 9.7.5 Recent Developments
- 9.8 Waters Corporation
- 9.8.1 Overview
- 9.8.2 Financials
- 9.8.3 Product Portfolio
- 9.8.4 Business Strategy
- 9.8.5 Recent Developments
- 9.9 Danaher Corporation
- 9.9.1 Overview
- 9.9.2 Financials
- 9.9.3 Product Portfolio
- 9.9.4 Business Strategy
- 9.9.5 Recent Developments
- 9.10 Roche Holding AG
- 9.10.1 Overview
- 9.10.2 Financials
- 9.10.3 Product Portfolio
- 9.10.4 Business Strategy
- 9.10.5 Recent Developments
- 9.11 Oxford Nanopore Technologies Ltd.
- 9.11.1 Overview
- 9.11.2 Financials
- 9.11.3 Product Portfolio
- 9.11.4 Business Strategy
- 9.11.5 Recent Developments
- 9.12 Pacific Biosciences of California Inc.
- 9.12.1 Overview
- 9.12.2 Financials
- 9.12.3 Product Portfolio
- 9.12.4 Business Strategy
- 9.12.5 Recent Developments
- 9.13 Eurofins Scientific
- 9.13.1 Overview
- 9.13.2 Financials
- 9.13.3 Product Portfolio
- 9.13.4 Business Strategy
- 9.13.5 Recent Developments
- 9.14 BGI Group
- 9.14.1 Overview
- 9.14.2 Financials
- 9.14.3 Product Portfolio
- 9.14.4 Business Strategy
- 9.14.5 Recent Developments
- 9.15 GenScript Biotech Corporation
- 9.15.1 Overview
- 9.15.2 Financials
- 9.15.3 Product Portfolio
- 9.15.4 Business Strategy
- 9.15.5 Recent Developments
- 9.16 NanoString Technologies Inc.
- 9.16.1 Overview
- 9.16.2 Financials
- 9.16.3 Product Portfolio
- 9.16.4 Business Strategy
- 9.16.5 Recent Developments
- 9.17 Takara Bio Inc.
- 9.17.1 Overview
- 9.17.2 Financials
- 9.17.3 Product Portfolio
- 9.17.4 Business Strategy
- 9.17.5 Recent Developments
- 9.18 GE Healthcare
- 9.18.1 Overview
- 9.18.2 Financials
- 9.18.3 Product Portfolio
- 9.18.4 Business Strategy
- 9.18.5 Recent Developments
- 9.19 Beckman Coulter Inc.
- 9.19.1 Overview
- 9.19.2 Financials
- 9.19.3 Product Portfolio
- 9.19.4 Business Strategy
- 9.19.5 Recent Developments
- 9.20 10x Genomics Inc.
- 9.20.1 Overview
- 9.20.2 Financials
- 9.20.3 Product Portfolio
- 9.20.4 Business Strategy
- 9.20.5 Recent Developments
- 9.21 Others.
- 9.21.1 Overview
- 9.21.2 Financials
- 9.21.3 Product Portfolio
- 9.21.4 Business Strategy
- 9.21.5 Recent Developments
- 9.1 Thermo Fisher Scientific Inc.
List Of Figures
Figures No 1 to 27
List Of Tables
Tables No 1 to 77
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2033
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Agilent Technologies Inc.
- Qiagen N.V.
- PerkinElmer Inc.
- Bio-Rad Laboratories Inc.
- Bruker Corporation
- Waters Corporation
- Danaher Corporation
- Roche Holding AG
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences of California Inc.
- Eurofins Scientific
- BGI Group
- GenScript Biotech Corporation
- NanoString Technologies Inc.
- Takara Bio Inc.
- GE Healthcare
- Beckman Coulter Inc.
- 10x Genomics Inc.
- Others
FAQs
The major driver for the Multiomics market is high demand in pharmaceuticals and growing adoption in crop breeding.
The “Cell Biology” had the largest share in the global market for Multiomics.
The “Single-cell Multiomics” category dominated the market in 2023.
The key players in the market are Thermo Fisher Scientific Inc., Illumina Inc., Agilent Technologies Inc., Qiagen N.V., PerkinElmer Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Waters Corporation, Danaher Corporation, Roche Holding AG, Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Eurofins Scientific, BGI Group, GenScript Biotech Corporation, NanoString Technologies Inc., Takara Bio Inc., GE Healthcare, Beckman Coulter Inc. , 10x Genomics Inc., Others.
“North America” had the largest share in the Multiomics Market.
The global market is projected to grow at a CAGR of 15.2% during the forecast period, 2024-2033.
The Multiomics Market size was valued at USD 2.7 Billion in 2024.